Introduction In type 2 diabetes, hepatic steatosis is common and contributes to cardiometabolic risk. SGLT2 inhibitors improve weight and glycemia, but whether they reduce liver fat through weight loss alone or via a direct hepatic effect has remained uncertain.
Introduction
In type 2 diabetes, hepatic steatosis is common and contributes to cardiometabolic risk. SGLT2 inhibitors improve weight and glycemia, but whether they reduce liver fat through weight loss alone or via a direct hepatic effect has remained uncertain.
Summary
This secondary analysis of a randomised, placebo-controlled trial studied 56 patients with type 2 diabetes assigned to placebo or dapagliflozin 10 mg for 12 months. Most participants (76%) had hepatic steatosis at baseline, and groups were comparable in metabolic risk and liver fat. Compared with placebo, dapagliflozin significantly reduced liver fat measured by MRI–proton density fat fraction (PDFF), alongside modest reductions in body weight and HbA1c. Crucially, mediation analysis showed that the reduction in liver fat was driven by a direct effect of dapagliflozin, while the indirect pathway via weight loss was not statistically significant. The findings suggest dapagliflozin can lower hepatic fat in T2D beyond its effects on weight and glycemic control, supporting further investigation of SGLT2 inhibitors as potential tools for managing metabolic dysfunction–associated steatotic liver disease.
Introduction: Chronic hepatitis B (CHB), hepatic steatosis, and type 2 diabetes mellitus (T2DM) frequently coexist, creating a growing clinical challenge. This multinational study evaluated whether T2DM independently influences liver histology in treatment-naïve CHB patients with...
Introduction: Metabolic dysfunction-associated steatohepatitis (MASH) remains a leading cause of cirrhosis, liver failure, and hepatocellular carcinoma, with limited treatment options. This study evaluated DT-109, a novel glycine-based tripeptide, as a gut-targeted therapy aimed at restoring...
Introduction: Metabolic dysfunction-associated steatohepatitis (MASH) remains a leading cause of cirrhosis, liver failure, and hepatocellular carcinoma, with limited treatment options. This study evaluated DT-109, a novel glycine-based tripeptide, as a gut-targeted therapy aimed at restoring...
Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD) is closely linked to obesity, diabetes, and cardiovascular disease. While both tirzepatide and SGLT2 inhibitors improve metabolic health, comparative real-world data on long-term liver and cardiovascular outcomes have...
Introduction: GLP-1 receptor agonists (GLP-1RAs) have revolutionized obesity treatment, producing substantial weight loss and cardiometabolic benefits. However, many patients discontinue therapy because of cost, adverse effects, or limited access, and weight regain frequently follows. This...
Introduction: The treatment landscape for metabolic dysfunction-associated steatohepatitis (MASH) is evolving rapidly with the emergence of incretin-based therapies. Beyond improving weight and glycemic control, these agents are showing promise in resolving steatohepatitis and slowing fibrosis...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.